About Oxular
Oxular is a company based in Oxford (United Kingdom) founded in 2014 was acquired by Regeneron Pharmaceuticals in January 2025.. Oxular has raised $57.53 million across 2 funding rounds from investors including Regeneron Pharmaceuticals, IP Group and Hovione. The company has 6 employees as of September 30, 2021. Oxular operates in a competitive market with competitors including Kriya Therapeutics, Annexon, Aldeyra, Nicox and Gyroscope, among others.
- Headquarter Oxford, United Kingdom
- Employees 6 as on 30 Sep, 2021
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Oxular Limited
- Date of Incorporation 27 Nov, 2014
- Jurisdiction OXFORD, ENGLAND
-
Annual Revenue
$2.1 M (USD)1348as on Oct 31, 2022
-
Net Profit
$-16.87 M (USD)-115as on Oct 31, 2022
-
EBITDA
$-21.01 M (USD)-119as on Oct 31, 2022
-
Total Equity Funding
$57.53 M (USD)
in 2 rounds
-
Latest Funding Round
$37 M (USD), Series B
Mar 01, 2021
-
Investors
Regeneron Pharmaceuticals
& 7 more
-
Employee Count
6
as on Sep 30, 2021
-
Acquired by
Regeneron Pharmaceuticals
(Jan 02, 2025)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Unlock access to complete
Unlock access to complete
Leadership Team
10 people
Operations Team
1 people
Finance and Accounting
1 people
Observer Team
1 people
Unlock access to complete
Funding Insights of Oxular
Oxular has successfully raised a total of $57.53M across 2 strategic funding rounds. The most recent funding activity was a Series B round of $37 million completed in March 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 2
- Last Round Series B — $37.0M
-
First Round
First Round
(19 Jul 2016)
- Investors Count 7
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Mar, 2021 | Amount | Series B - Oxular | Valuation | Forbion | |
| Jul, 2016 | Amount | Series A - Oxular | Valuation | Imperial Innovations |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Oxular
Oxular has secured backing from 8 investors, including venture fund and institutional investors. Prominent investors backing the company include Regeneron Pharmaceuticals, IP Group and Hovione. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital firm focused on lifescience and healthcare sectors
|
Founded Year | Domain | Location | |
|
Venture capital and advisory services are offered across multiple sectors.
|
Founded Year | Domain | Location | |
|
V-Bio Ventures is engaged in life science venture capital investment.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Oxular
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Oxular
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Oxular Comparisons
Competitors of Oxular
Oxular operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Kriya Therapeutics, Annexon, Aldeyra, Nicox and Gyroscope, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Developer of therapeutic solutions for the treatment of diabetes
|
|
| domain | founded_year | HQ Location |
Developer of antibodies to treat complement-mediated neurodegenerative diseases
|
|
| domain | founded_year | HQ Location |
Drug candidates for immune-mediated diseases are developed by Aldeyra.
|
|
| domain | founded_year | HQ Location |
Nitric oxide-based therapeutics for glaucoma and eye conditions are developed.
|
|
| domain | founded_year | HQ Location |
Mobile SDK developed for app engagement and monetization strategies.
|
|
| domain | founded_year | HQ Location |
Gene therapies for ocular and neurodegenerative diseases are developed.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Oxular
Frequently Asked Questions about Oxular
When was Oxular founded?
Oxular was founded in 2014 and raised its 1st funding round 2 years after it was founded.
Where is Oxular located?
Oxular is headquartered in Oxford, United Kingdom. It is registered at Oxford, Oxfordshire, United Kingdom.
Is Oxular a funded company?
Oxular is a funded company, having raised a total of $57.53M across 2 funding rounds to date. The company's 1st funding round was a Series A of $20.53M, raised on Jul 19, 2016.
How many employees does Oxular have?
As of Sep 30, 2021, the latest employee count at Oxular is 6.
What is the annual revenue of Oxular?
Annual revenue of Oxular is $2.1M as on Oct 31, 2022.
What does Oxular do?
Founded in 2014 in Oxford, United Kingdom, operations center on the development of drug delivery platforms and therapeutics within the ophthalmology sector. Key programs, including OXU-001 and OXU-003, facilitate targeted drug delivery to posterior ocular tissues. The Oxusphere, a biodegradable polymer system containing drugs, is utilized alongside the Oxulumis, a semi-automated ocular administration device. Indications such as age-related macular degeneration, diabetic macular edema, and rare ophthalmic disorders are being explored.
Who are the top competitors of Oxular?
Oxular's top competitors include Annexon, Alimera Sciences and MeiraGTx.
Who are Oxular's investors?
Oxular has 8 investors. Key investors include Regeneron Pharmaceuticals, IP Group, Hovione, Consort Medical, and Imperial Innovations.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.